2023 World Conference on Lung Cancer (Posters)-EP12.01. Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations

EP12.01. Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations - PDF(Slides)

Back to course

Pdf Summary

A case study presented by Tao Tao from The First Affiliated Hospital of Bengbu Medical College in China describes the exceptional response to a treatment called Aumolertinib in a patient with advanced non-small cell lung cancer (NSCLC) who had rare EGFR exon20 V774M and S768I mutations. Previous studies have shown that NSCLC patients with EGFR exon20 mutations tend to be less sensitive to current treatment options. However, in this case, third-generation EGFR-TKI Aumolertinib was found to be effective against these complex rare mutations. The patient, a 52-year-old female with left upper lobe adenocarcinoma and mediastinal lymph nodes and pleural metastases, was in stage IVA of the disease. Surgical resection was deemed pointless, and the patient had no underlying diseases or history of malignancy. Aumolertinib was administered as a first-line treatment, and regular follow-up scans showed significant shrinkage of the tumor. The best response was a partial response, and the patient had a progression-free survival of 11 months. However, the patient later developed multiple brain metastases and underwent whole brain radiotherapy. Two months later, disease progression was observed in the lung and brain, and the patient is now being treated with a combination of Aumolertinib and anlotinib. This is the first report of first-line treatment with Aumolertinib for NSCLC patients with EGFR exon20 V774M/S768I mutations, and it showed remarkable efficacy with an 11-month progression-free survival. This case provides a promising treatment regimen for patients with this rare mutation of the EGFR exon20.

Asset Subtitle

Tao Tao

Meta Tag

Speaker Tao Tao

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Aumolertinib

NSCLC

EGFR exon20 mutations

rare mutations

third-generation EGFR-TKI

tumor shrinkage

partial response

progression-free survival

brain metastases

combination treatment